The Filing Desk

Beta Bionics

BBNX · Nasdaq · Health Care · Financials, fiscal 2023 to 2025

BBNX · Last close · November 13, 2026
$16.42
Value Beta Bionics yourself

Beta Bionics' revenue rose 53.9% to $100 million in fiscal 2025. Its operating margin was −71.5%, down from −69.5% a year earlier. Free cash flow was −$56 million. The diluted share count rose 536.7%.

BETA BIONICS, INC. Latest fiscal year ended December 31, 2025 10-K filed February 24, 2026 · 0001193125-26-067065 Updated
Revenue
$100M
53.9%
Operating margin
−71.5%
2.0 pts
Net income
−$73M
 
Free cash flow
−$56M
 
Return on equity
−346.5%
 
Market cap
$764M
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Beta Bionics does

Beta Bionics makes the iLet Bionic Pancreas, an automated insulin delivery system for people with diabetes who need insulin. It uses an adaptive closed-loop algorithm, meaning software that adjusts insulin doses on its own to simplify daily management. The U.S. Food and Drug Administration cleared the iLet for Type 1 diabetes in adults and children six and older, and it launched in the United States in May 2023.

The company has no other commercial products. It relies on sales of the iLet and related single-use products for all of its revenue. It says its installed base had grown to 35,011 iLets by the end of 2025. It competes with makers of other insulin pumps and diabetes devices, most of which have far greater resources.

Beta Bionics describes itself as a commercial-stage company with limited experience in marketing and selling its products. Its device is under a post-market surveillance order from the FDA.

Its biggest risks, as it describes them

  • It has a limited sales history and has lost money since it started.
  • All its revenue comes from the iLet and related single-use products.
  • Competitors with far greater resources could win customers or make the iLet less desirable.
  • The FDA's post-market surveillance order could force changes to, or a recall of, the iLet.
  • It may need to raise more money, which may not be available on acceptable terms.
From Beta Bionics's annual report on Form 10-K, filed February 24, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Beta Bionics lost money in fiscal 2025: a net loss of $73 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY23FY24FY25
Cash and short-term investments97104219
Debt incl. finance leases———
Net debt (negative means net cash)———
Net debt to EBITDA———
Debt to equity———
Interest coverage———
Current ratio9.8x6.3x8.7x
Quick ratio9.7x5.7x8.0x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Beta Bionics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of Beta Bionics reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY24FY25
Piotroski F-score——
Rule of 40363.6%−2.1%
Altman Z''−7.106.94
Accruals ratio−5.0%−9.3%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY24FY25
Net income is positiveFailFail
Cash from operations is positiveFailFail
Return on assets rose—Pass
Cash from operations exceeds net incomePassPass
Debt fell relative to assets——
Current ratio roseFailPass
Share count didn't riseFailFail
Gross margin rosePassPass
Revenue rose relative to assets—Pass
F-score——
Companies that report no gross profit are scored on the other eight.

Compare

Put Beta Bionics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Beta BionicsFY2553.9%−71.5%−56.1%———
Butterfly NetworkFY2519.0%−88.5%−16.4%———Compare
Kestra Medical TechnologiesFY2659.0%−141.6%−122.6%——4Compare
CeribellFY2536.1%−65.6%−46.7%———Compare
Delcath SystemsFY25129.1%0.8%24.6%2.8%−101.4x6Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

3 years of figures

Fiscal yearFY23FY24FY25
Income statement
Revenue1265100
Revenue growth—442.9%53.9%
Gross profit63656
Research and development182635
Operating income−36−45−72
Net income−44−55−73
Diluted EPS (US$)−8.31−8.60−1.81
Diluted shares (millions)5640
Cash flow
Cash from operations−32−48−51
Capital expenditure035
Free cash flow−33−52−56
Dividends paid000
Share buybacks000
Acquisitions000
Stock-based compensation6616
Balance sheet at fiscal year end
Cash and short-term investments97104219
Debt incl. finance leases———
Total assets110150329
Total liabilities517441
Shareholders' equity−203−245288
Margins and ratios
Gross margin52.6%55.1%55.4%
Operating margin−298.9%−69.5%−71.5%
Net margin−367.6%−84.1%−73.0%
Free cash flow margin−273.8%−79.3%−56.1%
Rule of 40 (growth + FCF margin)—363.6%−2.1%
Return on capital———
Return on equity——−346.5%
Return on assets—−42.2%−30.6%
Net debt to EBITDA———
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Beta Bionics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Beta Bionics.